Indication
In combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.
Medicine details
- Medicine name:
- durvalumab (Imfinzi)
- SMC ID:
- SMC2735
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 03 March 2025